• 1
    Anaya JM, Talal N. Sjögren's syndrome comes of age. Semin Arthritis Rheum 1999; 28: 3559.
  • 2
    Anaya JM, Talal N. Sjögren's syndrome and connective tissue diseases associated with other immunologic disorders. In: KoopmanW, editor. Arthritis and allied conditions. 13th ed. Philadelphia: Williams & Wilkins; 1997. p. 156180.
  • 3
    Fox PC, Brennan M, Pillemer S, Radfar L, Yamano S, Baum J. Sjögren's syndrome: a model for dental care in the 21st century. J Am Dent Assoc 1998; 129: 71928.
  • 4
    Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am 1992; 18: 57189.
  • 5
    Fox RI. Sjögren's syndrome: immunobiology of exocrine gland dysfunction. Adv Dent Res 1996; 10: 3540.
  • 6
    Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjögren's syndrome. Crit Rev Oral Biol Med 1996; 7: 14458.
  • 7
    Fox RI, Maruyama T. Pathogenesis and treatment of Sjögren's syndrome. Curr Opin Rheumatol 1997; 9: 3939.
  • 8
    Atkinson JC, Fox PC. Sjögren's syndrome: oral and dental considerations. J Am Dent Assoc 1993; 124: 7486.
  • 9
    Wu AJ, Fox PC. Sjögren's syndrome. Semin Dermatol 1994; 13: 13843.
  • 10
    Friedlaender MH. Ocular manifestations of Sjögren's syndrome: keratoconjunctivitis sicca. Rheum Dis Clin North Am 1992; 18: 591608.
  • 11
    Fox PC. Management of dry mouth. Dent Clin North Am 1997; 41: 86376.
  • 12
    Papas AS, Fernancez MM, Castano RA, Gallagher SC, Trivedi M, Shrotriya RC. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögren's syndrome. Adv Exp Med Biol 1998; 438: 9738.
  • 13
    Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, Tran-Johnson T, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999; 158: 17481.
  • 14
    Fox RI, Petrone D, Condemi J, Fife R, Delgin P. Randomized, placebo-controlled trial of SNI-2011, a novel M3 muscarinic receptor agonist, for treatment of Sjögren's syndrome [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S80.
  • 15
    Stewart WE II. The interferon system. New York: Springer-Verlag; 1979.
  • 16
    Witherspoon LR. The interferons—clinical applications and new technologies. J Nucl Med 1984; 25: 81721.
  • 17
    Djeu JY, Stocks N, Zoon K, Stanton GJ, Timonen T, Herberman RB. Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes virus. J Exp Med 1982; 156: 122234.
  • 18
    Cummins JM, Beilharz MW, Krakowka S. Oral use of interferon. J Interferon Cytokine Res 1999; 19: 8537.
  • 19
    Shiozawa S, Kuroki Y, Yoshihara R, Chihara K, Hirata M, Tanaka T, et al. Increasing effect of oral interferon alpha in saliva secretion of Sjögren's syndrome patients. Annual Meeting of the Japan Rheumatology Association; 1993; Abstract W-12-10.
  • 20
    Shiozawa K, Tanaka Y, Yoshihara R, Hirata M, Kabebuma S, Shiozawa S. Effect of orally administered interferon alpha on saliva production in Sjögren's syndrome. Annual Meeting of the Japan Rheumatology Association; 1994; Abstract F586.
  • 21
    Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res 1998; 18: 25562.
  • 22
    Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB, IFN Protocol Study Group. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-α administered by the oral mucosal route: a Phase II clinical trial. J Interferon Cytokine Res 1999; 19: 94351.
  • 23
    Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European community. Arthritis Rheum 1993; 36: 3407.
  • 24
    Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study: the European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis 1996; 55: 11621.
  • 25
    Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993; 694: 727.
  • 26
    Mulligan R, Navazesh M, Wood GJ. A pilot study comparing three salivary collection methods in an adult population with salivary gland hypofunction. Spec Care Dentist 1995; 15: 1547.
  • 27
    Sugimoto K, Yuen S. Interferon and preparations containing interferon. 1981. U.S. Patent No. 4,276,282.
  • 28
    Senn S. Statistical issues in drug development. New York: John Wiley & Sons; 1997. p. 158.
  • 29
    Southie C, Papas A, Stack K, Harrinton D. Dietary patterns in a drug induced xerostomic population. J Dent Res 1998; 77: 283.
  • 30
    Papas A, Palmer C. Do women with Sjögren's have diets with high cariogenic potential? 1st International Women in Dental Education Conference, Cannes, France; 1998.
  • 31
    Calvo J, Papas A. Do medication-induced xerostomia subjects have more caries prevalence than non-medicated subjects? J Dent Res 2002; 81: Abstract 985.
  • 32
    Mandel ID. The function of saliva. J Dent Res 1987; 66: 6237.
  • 33
    Mandel ID. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc 1989; 119: 298304.
  • 34
    Smith JK, Siddiqui AA, Modica LA, Dykes R, Simmons C, Schmidt J, et al. Interferon upregulates gene expression of Aquaporin-5 in human parotid glands. J Interferon Cytokine Res 1999; 19: 92935.
  • 35
    Tsubota K, Hirai S, King LS, Agre P, Ishida N. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome. Lancet 2001; 357: 6889.
  • 36
    Steinfeld S, Cogan E, King LS, Agre P, Kiss R, Delporte C. Abnormal distribution of aquaporin 5 water channel protein in salivary glands from Sjögren's syndrome patients. Lab Invest 2001; 81: 1438.